"NGR005: Pilot study of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin-based regimen in patients wit metastatic colorectal cancer"
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2013
At a glance
- Drugs NGR-TNF (Primary) ; Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 22 Sep 2010 Status changed from active, no longer recruiting to completed, according to a MolMed media release.
- 22 Sep 2010 Results published in Annals of Oncology, according to a MolMed media release.